ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A trio of former executives at Johnson & Johnson has banded together to launch a start-up focused on next-generation biologics. Former J&J oncology R&D head Peter F. Lebowitz, former head of Janssen Biotherapeutics Sanjaya Singh, and former J&J vice president and head of oncology discovery and external innovation Joe Erhardt are behind Third Arc Bio. The company aims to develop antibodies that engage T cells such that they can be used to treat solid-tumor cancers and inflammatory and immunological diseases. The company has $165 million in venture backing from Goldman Sachs and AbbVie, among others.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter